Corium Announces Positive Topline Results From Phase 1 Clinical Study of Transdermal CorplexTM Memantine as a Potential Treatment of Alzheimer’s Disease
Demonstrates Pharmacokinetic Profile Supporting the Feasibility of Sustained Transdermal Delivery Webcast and Conference Call Today at 5:00 p.m. ET ( 2:00 p.m. PT ) MENLO PARK, Calif. , Feb. 22, 2016 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage…
Corium Reports First Quarter Fiscal 2016 Financial Results
MENLO PARK, Calif. , Feb. 08, 2016 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results from operations…
Corium Announces Positive Topline Results From Phase 1 PK Clinical Study of Once-Weekly Transdermal CorplexTM Donepezil as a Potential Treatment of Alzheimer’s Disease
Demonstrates Sustained Delivery, Acceptable Skin Tolerability, and Pharmacokinetic Profile to Support the Feasibility of Once-Weekly Dosing Webcast and Conference Call Today at 5:00 p.m. ET ( 2:00 p.m. PT ) MENLO PARK, Calif. , Feb. 03, 2016 (GLOBE NEWSWIRE) — Corium International, Inc….
Corium to Report First Quarter Fiscal year 2016 Financial Results on Monday, February 8, 2016
MENLO PARK, Calif. , Feb. 01, 2016 (GLOBE NEWSWIRE) — Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the first fiscal quarter ended December 31, 2015 on Monday, February 8, 2016 after the close of the U.S….
